Theseus Pharmaceuticals, Inc , a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients.
infoTheseus Pharmaceuticals is a micro cap stock with a total market cap of 137.35M.
infoThey trade on the NASDAQ and had their IPO 1 year and 10 months ago.
infoTheseus Pharmaceuticals currently employs 38 people.
infoAs of Wednesday, Aug 23 2023, Theseus Pharmaceuticals’s share price is $3.15.
News Relating to Theseus Pharmaceuticals
Zacks Investment Research
Down -65.65% in 4 Weeks, Here’s Why You Should You Buy the Dip in Theseus Pharmaceuticals, Inc. (THRX)
Friday Aug 11 2023 at 10:47
The heavy selling pressure might have exhausted for Theseus Pharmaceuticals, Inc. (THRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks Investment Research
New Strong Buy Stocks for July 19th
Wednesday Jul 19 2023 at 09:52
SOHO, FUTU, NEOG, OPK and THRX have been added to the Zacks Rank #1 (Strong Buy) List on July 19, 2023.
Zacks Investment Research
After Plunging -69.57% in 4 Weeks, Here’s Why the Trend Might Reverse for Theseus Pharmaceuticals, Inc. (THRX)
Tuesday Jul 18 2023 at 11:21
The heavy selling pressure might have exhausted for Theseus Pharmaceuticals, Inc. (THRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks Investment Research
Theseus (THRX) Falls 72% on Decision to Discontinue GIST Study
Monday Jul 17 2023 at 12:02
Theseus (THRX) announces the discontinuation of enrollment in its phase I/II study of THE-630 in patients with gastrointestinal stromal tumors due to observed adverse reactions. The stock falls 72%.
InvestorPlace
Why Is Theseus Pharmaceuticals (THRX) Stock Down 68% Today?
Friday Jul 14 2023 at 08:46
Theseus Pharmaceuticals (NASDAQ: THRX ) stock is falling hard on Friday after the company announced poor results from a Phase 1/2 clinical trial. According to a press release from Theseus Pharmaceuticals, the company is no longer enrolling patients in its clinical trial for THE-630 in patients with gastrointestinal stromal tumors (GIST).
The Motley Fool
Why These 2 Biotech Stocks Made Big Moves Late Thursday
Thursday Jul 13 2023 at 19:11
Stock markets kept climbing on Thursday. Acadia stock moved higher as the company expanded a key licensing agreement.
Market Watch
Theseus Pharmaceuticals stock plummets after cancer drug development stopped
Thursday Jul 13 2023 at 17:14
Theseus Pharmaceuticals Inc. THRX, -3.74% shares plummeted after hours Thursday after the biotech drug maker discontinued enrolling patients in the study of a cancer drug it no longer intend to develop. Theseus shares plunged as much as 75% in the extended session Thursday, following a 3.7% decline to close the regular session at $9.52.
Zacks Investment Research
Wall Street Analysts See a 128.83% Upside in Theseus Pharmaceuticals, Inc. (THRX): Can the Stock Really Move This High?
Tuesday Apr 04 2023 at 11:24
The average of price targets set by Wall Street analysts indicates a potential upside of 128.8% in Theseus Pharmaceuticals, Inc. (THRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks Investment Research
4 Biotech Stocks to Consider for Your Portfolio in 2023
Tuesday Mar 21 2023 at 13:00
New drug approvals and pipeline progress should maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position CRSP, LGND, THRX and KALA well amid volatility.
Zacks Investment Research
What Makes Theseus Pharmaceuticals, Inc. (THRX) a New Buy Stock
Tuesday Mar 14 2023 at 13:44
Theseus Pharmaceuticals, Inc. (THRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
24/7 Wall Street
The 5 Best and Worst Performing Small-Cap Stocks in January 2023
Monday Feb 13 2023 at 22:51
Small-cap stocks are expected to perform well this year. The Bank of America Securities, in fact, is asking investors to consider small caps this year to hedge against a declining market.
PRNewsWire
Theseus Pharmaceuticals to Present Preclinical Data Characterizing Next-Generation Epidermal Growth Factor Receptor (EGFR) Inhibitors at the 2022 American Association for Cancer Research (AACR) Annual Meeting
Tuesday Mar 08 2022 at 17:01
CAMBRIDGE, Mass., March 8, 2022 /PRNewswire/ — Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that the Company will present a poster highlighting the characterization of potent and selective next-generation EGFR inhibitors at the American Association for Cancer Research (AACR) 2022 Annual Meeting, being held April 8-13, 2022 in New Orleans, Louisiana.
PRNewsWire
Theseus Pharmaceuticals to Participate Virtually in SVB Leerink Global Healthcare Conference
Wednesday Feb 09 2022 at 07:30
CAMBRIDGE, Mass., Feb. 9, 2022 /PRNewswire/ — Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (“Theseus”), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that Tim Clackson, Ph.D.
Stockmarketcom
Top Stocks To Invest In Right Now? 5 Health Care Stocks To Watch
Tuesday Jan 18 2022 at 14:56
Check out these health care firms taking center stage in the stock market now.
Benzinga
5 Beaten Down Biotech Stocks That Could Bounce Big In 2022
Monday Dec 27 2021 at 11:12
Biotech stocks remain poised to eke out modest gains for 2021 after the stellar gains of the previous year. COVID-19 drug and vaccine developers experienced volatility throughout 2021 amid delays in programs and the reemergence of variant strains.
Theseus Pharmaceuticals Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Theseus Pharmaceuticals’s Altman Z-score is 6.81 which is in the safe zone. This indicates the company is financially stable and less likely to experience financial distress or bankruptcy.
Derived from SEC.GOV filing dataopen_in_new
Theseus Pharmaceuticals Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, 2 insiders have bought $2.93M of common stock in Theseus Pharmaceuticals on the stock market with no insider selling.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Theseus Pharmaceuticals’s Income Quality of 0.64 is in line with its Industry Group of 0.69 (-7.2% lower)
Theseus Pharmaceuticals’s Income Quality of 0.64 is in line with its Major Industry Group of 0.71 (-9.9% lower)
Theseus Pharmaceuticals’s Income Quality of 0.64 is lower than its Sector of 0.75 (-14.7% lower)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Theseus Pharmaceuticals’s Current Ratio of 27.83 is greater than its Industry Group of 4.76 (484.7% greater)
Theseus Pharmaceuticals’s Current Ratio of 27.83 is greater than its Major Industry Group of 4.32 (544.2% greater)
Theseus Pharmaceuticals’s Current Ratio of 27.83 is greater than its Sector of 2.6 (970.4% greater)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-2.46 & -1.27)
Cannot compare a negative PE Ratio (-2.46 & -1.1)
Cannot compare a negative PE Ratio (-2.46 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Theseus Pharmaceuticals’s PB Ratio of 0.59 is lower than its Industry Group of 1.34 (-56.0% lower)
Theseus Pharmaceuticals’s PB Ratio of 0.59 is lower than its Major Industry Group of 1.4 (-57.9% lower)
Theseus Pharmaceuticals’s PB Ratio of 0.59 is lower than its Sector of 1.62 (-63.6% lower)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Theseus Pharmaceuticals’s ROE of -0.24 is greater than its Industry Group of -0.44 (45.5% greater)
Theseus Pharmaceuticals’s ROE of -0.24 is greater than its Major Industry Group of -0.38 (36.8% greater)
Theseus Pharmaceuticals’s ROE of -0.24 is lower than its Sector of -0.03 (-700.0% lower)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Theseus Pharmaceuticals’s ROCE of -0.28 is greater than its Industry Group of -0.42 (33.3% greater)
Theseus Pharmaceuticals’s ROCE of -0.28 is greater than its Major Industry Group of -0.37 (24.3% greater)
Theseus Pharmaceuticals’s ROCE of -0.28 is lower than its Sector of -0.04 (-600.0% lower)
Derived from SEC.GOV filing dataopen_in_new